Advertisement
Canada markets open in 3 hours 12 minutes
  • S&P/TSX

    22,465.37
    +165.57 (+0.74%)
     
  • S&P 500

    5,308.13
    +4.86 (+0.09%)
     
  • DOW

    39,806.77
    -196.82 (-0.49%)
     
  • CAD/USD

    0.7338
    -0.0004 (-0.06%)
     
  • CRUDE OIL

    78.84
    -0.96 (-1.20%)
     
  • Bitcoin CAD

    96,996.23
    +5,576.84 (+6.10%)
     
  • CMC Crypto 200

    1,527.97
    +39.42 (+2.65%)
     
  • GOLD FUTURES

    2,419.30
    -19.20 (-0.79%)
     
  • RUSSELL 2000

    2,102.50
    +6.78 (+0.32%)
     
  • 10-Yr Bond

    4.4370
    +0.0170 (+0.38%)
     
  • NASDAQ futures

    18,740.75
    -22.25 (-0.12%)
     
  • VOLATILITY

    12.47
    +0.32 (+2.63%)
     
  • FTSE

    8,387.12
    -37.08 (-0.44%)
     
  • NIKKEI 225

    38,946.93
    -122.75 (-0.31%)
     
  • CAD/EUR

    0.6747
    -0.0009 (-0.13%)
     

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

The company also continues to benefit from sales of blockbusters including blood thinner Eliquis and oncology drug Ibrance. In fact, Pfizer expects patent losses alone to lead to $17 billion in lost revenue from 2025 through 2030. In spite of these upcoming obstacles, is Pfizer still a buy?